Pharma CEO: Daraprim Price Hike is ‘Terribly Unfortunate’

Dr. Francois Nader was CEO of NPS Pharmaceuticals, and recently sold it to Shire Pharmaceuticals for $5.3B. He shares with Privcap his analysis on the Daraprim pricing controversy, in which a new owner of this drug vastly increased the price, causing many to wonder what the effects will be on the pharmaceutical industry.

Register now to watch this video and access all content.

It's FREE!

Email*
Username*
Name*
First Last
Title*
Firm Name*
Firm Type*
Zip Code*
Password*
Enter Password Confirm Password
Hidden
Choose your newsletters
CHOOSE YOUR NEWSLETTERS:
- Private Equity
- Real Estate
Choose your newsletters*
I agree to the Privcap terms of use and privacy policy
- Yes
Already a subscriber? Sign In
Phone
This field is for validation purposes and should be left unchanged.

- Media Partners

Privcap Email Updates

Subscribe to receive email notifications whenever new talks are published.

Pharma CEO: Daraprim Price Hike is ‘Terribly Unfortunate’

Register now to watch this video and access all content.

It's FREE!

Already a subscriber? Sign In

Privcap Email Updates